Australian PED Research Association
APEDRAAustralian Performance Enhancing Drugs Research Association
Performance-enhancing drugs are discussed in extremes. Safety begins with clear education.
APEDRA is an independent, research-focused editorial team that reviews and interprets peer-reviewed literature on performance-enhancing drugs and related research chemicals in Australia. Our mission is to make PED research clear, independent and accessible through responsible, evidence-based analysis.
- Compound reviews
- 51
- Vendors assessed
- 19
- Commercial affiliations
- 0
Our position
Understanding the evidence, the risks and the unknowns is essential to informed decisions
Debate around performance-enhancing drugs tends to collapse into promotion or prohibition. Neither helps someone weighing a decision about their own body. We publish what the research establishes, what it only suggests, and what remains genuinely unknown — alongside the importance of medical guidance in sport, health and performance.
Evidence-based analysis
Every review starts with the published literature: what was measured, in whom, at what dose, and what the data does not show.
Harm reduction first
We assume readers are making decisions already. Clear risk information and monitoring guidance reduce harm more effectively than silence.
Independent by design
No supplier funds our analysis, and no vendor can purchase a rating, placement or favourable review.
Plain, accurate language
Complex pharmacology explained without dilution, hype or moral framing — including where the evidence is weak or absent.
Latest analysis
Recent compound reviews
Ostarine (enobosarm, MK-2866): what the trial data actually shows
Enobosarm is the most extensively studied SARM in humans, with published phase II data in older adults and cancer-related muscle wasting. Lean mass ga…
Evidence base: ModerateSARMsLigandrol (LGD-4033): potency, suppression and reported liver injury
LGD-4033 has a single well-known phase I safety and tolerability study in healthy men plus a scattering of case reports. It suppresses endogenous test…
Evidence base: LimitedPeptidesGrowth hormone secretagogues (CJC-1295, ipamorelin, GHRP-2/6)
Secretagogues reliably raise GH and IGF-1 in short human studies. What they do to body composition, performance or long-term health in healthy adults …
Evidence base: LimitedSafety
Key facts, risks and monitoring
What PED use actually involves in an Australian context: unregulated product quality, documented health risks by class, sensible bloodwork, the red flags that need urgent attention, and why medical guidance is not optional.
Read the safety section →Vendor assessment
How Australian suppliers compare
We assess 19 Australian-facing vendors on verified review volume, website quality and navigation, shipping and returns policies, money-back guarantees and product range — with the methodology published in full.
Open the comparison →Reader tool
Summarise any paper in plain language
Found a study cited by a supplier, a forum or one of our reviews? Paste its abstract into our summariser and get a plain-language breakdown: what was actually measured, how strong the evidence is, and the limitations the headline tends to leave out.
- Study design, findings and evidence strength
- Limitations, confounders and what the study cannot tell you
- Nothing is stored — your text is processed and discarded
AI-assisted. Always verify against the original paper.
AI-generated summaries can be wrong. Always check the original paper. This tool is educational, not medical advice, and text you paste is not stored. Open the full summariser page →
Important
APEDRA does not sell, supply, source or encourage the use of any substance. Our material is educational and harm-reduction focused and is not a substitute for advice from a qualified medical practitioner who knows your history.